NYSE:KDMNKadmon Stock Price, Forecast & News

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KDMN stock has increased by 35.6% and is now trading at $4.72. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

Kadmon is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Kadmon.

Kadmon Holdings Inc (NYSE:KDMN) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.05. The firm earned $6.74 million during the quarter, compared to the consensus estimate of $0.38 million. Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%. View Kadmon's earnings history.

5 analysts have issued 1 year target prices for Kadmon's stock. Their forecasts range from $7.00 to $25.00. On average, they expect Kadmon's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 154.2% from the stock's current price. View analysts' price targets for Kadmon.

Press coverage about KDMN stock has been trending negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kadmon earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the immediate future. View the latest news about Kadmon.

Some companies that are related to Kadmon include Axsome Therapeutics (AXSM), Insmed (INSM), Karuna Therapeutics (KRTX), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), Opko Health (OPK), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), Uniqure (QURE), Corcept Therapeutics (CORT) and Eidos Therapeutics (EIDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Iovance Biotherapeutics (IOVA), Applied Materials (AMAT), Biocept (BIOC), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Global Blood Therapeutics (GBT).

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KDMN stock can currently be purchased for approximately $4.72.

Kadmon has a market capitalization of $755.34 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe.

The official website for Kadmon is www.kadmon.com.

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]